Literature DB >> 26781461

Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells.

Nahid Eskandari1,2, Fatemeh Tashrifi3,2, Reza Bastan4, Alrieza Andalib3, Zahra Yousefi3, Peter T Peachell5.   

Abstract

Cyclic nucleotide phosphodiesterase (PDE) exists as multiple molecular forms. Of the 11 families of PDE identified so far, PDE4, a cAMP-specific PDE, has been identified as the major isoform regulating inflammatory activity. The principle aim of the present study was to determine whether human basophils and human lung mast cells express PDE4. Four sub-classes of PDE4 (A, B, C, and D) have been identified and expression of these was determined by RT-CPR and by western blotting. In basophils, prominent expression of mRNA for PDE4A and PDE4D was observed whereas little if any expression of PDE4B and PDE4C was detected. These findings were paralleled by immunoblotting experiments as human basophils were found to express PDE4A and PDE4D with little evidence for the presence of either PDE4B or PDE4C. By contrast, human lung mast cells expressed very little, if any, mRNA for PDE4 sub-classes although, in some preparations, some modest levels of mRNA for PDE4D were detected. However, there was no evidence, at the protein level, that mast cells express PE4. Overall, these data indicate that basophils express PDE4 (4A and 4D) whereas human lung mast cells do not.
© The Author(s) 2016.

Entities:  

Keywords:  PCR; allergy; basophil; drug; lung; mast cell

Mesh:

Substances:

Year:  2016        PMID: 26781461      PMCID: PMC5806836          DOI: 10.1177/0394632015626150

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  24 in total

Review 1.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

Review 2.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

Review 3.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

Authors:  T J Torphy
Journal:  Am J Respir Crit Care Med       Date:  1998-02       Impact factor: 21.405

4.  Regulation of human basophil and lung mast cell function by cyclic adenosine monophosphate.

Authors:  P T Peachell; D W MacGlashan; L M Lichtenstein; R P Schleimer
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

5.  Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart.

Authors:  P Han; X Zhu; T Michaeli
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

Review 6.  Modulation of inflammation and immunity by cyclic AMP.

Authors:  H R Bourne; L M Lichtenstein; K L Melmon; C S Henney; Y Weinstein; G M Shearer
Journal:  Science       Date:  1974-04-05       Impact factor: 47.728

7.  Multiple cyclic nucleotide phosphodiesterases.

Authors:  J A Beavo; M Conti; R J Heaslip
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

8.  Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.

Authors:  Susan J Smith; Steven Brookes-Fazakerley; Louise E Donnelly; Peter J Barnes; Mary S Barnette; Mark A Giembycz
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-10-04       Impact factor: 5.464

9.  Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation.

Authors:  M Shichijo; Y Shimizu; K Hiramatsu; N Inagaki; K Tagaki; H Nagai
Journal:  Int Arch Allergy Immunol       Date:  1997-12       Impact factor: 2.749

Review 10.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

Authors:  Brian J Lipworth
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

View more
  4 in total

Review 1.  Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells.

Authors:  Pio Conti; Francesco Carinci; Gianfranco Lessiani; Enrico Spinas; Spyridon K Kritas; Gianpaolo Ronconi; Alessandro Caraffa; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

Review 2.  Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers).

Authors:  Pio Conti; Alessandro Caraffa; Gianpaolo Ronconi; Chiara M Conti; Spiros K Kritas; Filiberto Mastrangelo; Lucia Tettamanti; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

Review 3.  Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke.

Authors:  Haitao Wang; Uma Gaur; Jiao Xiao; Bingtian Xu; Jiangping Xu; Wenhua Zheng
Journal:  Int J Biol Sci       Date:  2018-10-03       Impact factor: 6.580

Review 4.  Clinical Implication of Phosphodiesterase-4-Inhibition.

Authors:  Martin Alexander Schick; Nicolas Schlegel
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.